Kory James Wentworth Entrada Therapeutics, Inc. (TRDA) insider trading activity

Kory James Wentworth is Chief Financial Officer of Entrada Therapeutics, Inc.. Currently has a direct ownership of 83,170 shares of TRDA, which is worth approximately $1.16 Million. The most recent transaction as insider was on Mar 15, 2024, when has been sold 9,000 shares (Common Stock) at a price of $2.1 per share, resulting in proceeds of $18,900. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 83.2K

0% 3M change

126.33% 12M change

Total Value Held $1.16 Million

KORY JAMES WENTWORTH Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 15 2024	BUY Exercise of conversion of derivative security	$18,900 $2.1 p/Share	9,000 Added 9.76%	83,170 Common Stock
Mar 06 2024	SELL Open market or private sale	$50,298 $12.31 p/Share	4,086 Reduced 5.22%	74,170 Common Stock
Mar 05 2024	SELL Payment of exercise price or tax liability	$18,063 $12.28 p/Share	1,471 Reduced 1.85%	78,256 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$9,597 $12.9 p/Share	744 Reduced 0.92%	79,727 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	30,900 Added 27.75%	80,471 Common Stock
Dec 26 2023	SELL Open market or private sale	$1,566 $16.67 p/Share	94 Reduced 0.19%	49,571 Common Stock
Dec 26 2023	BUY Exercise of conversion of derivative security	$197 $2.1 p/Share	94 Added 0.19%	49,665 Common Stock

Dec 22 2023	SELL Open market or private sale	$161,867 $15.86 p/Share	10,206 Reduced 17.07%	49,571 Common Stock
Dec 22 2023	BUY Exercise of conversion of derivative security	$21,432 $2.1 p/Share	10,206 Added 14.58%	59,777 Common Stock
Dec 21 2023	SELL Open market or private sale	$33,154 $15.07 p/Share	2,200 Reduced 4.25%	49,571 Common Stock
Dec 21 2023	BUY Exercise of conversion of derivative security	$4,620 $2.1 p/Share	2,200 Added 4.08%	51,771 Common Stock
Sep 06 2023	SELL Open market or private sale	$13,053 $13.74 p/Share	950 Reduced 1.88%	49,571 Common Stock
Sep 05 2023	SELL Payment of exercise price or tax liability	$6,159 $14.46 p/Share	426 Reduced 0.84%	50,521 Common Stock
Sep 01 2023	BUY Grant, award, or other acquisition	-	14,200 Added 21.8%	50,947 Common Stock
Jul 11 2023	SELL Open market or private sale	$69,912 $18.0 p/Share	3,884 Reduced 9.56%	36,747 Common Stock
Jul 11 2023	BUY Exercise of conversion of derivative security	$8,156 $2.1 p/Share	3,884 Added 8.73%	40,631 Common Stock
Jul 10 2023	SELL Open market or private sale	$109,965 $17.98 p/Share	6,116 Reduced 14.27%	36,747 Common Stock
Jul 10 2023	BUY Exercise of conversion of derivative security	$12,843 $2.1 p/Share	6,116 Added 12.49%	42,863 Common Stock
Jun 29 2023	BUY Exercise of conversion of derivative security	$18,459 $2.1 p/Share	8,790 Added 19.3%	36,747 Common Stock
Jun 21 2023	SELL Open market or private sale	$262,675 $15.01 p/Share	17,500 Reduced 38.5%	27,957 Common Stock
Jun 21 2023	BUY Exercise of conversion of derivative security	$36,750 $2.1 p/Share	17,500 Added 27.8%	45,457 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$11,658 $11.6 p/Share	1,005 Reduced 2.24%	43,904 Common Stock
Mar 02 2023	SELL Open market or private sale	$18,954 $10.85 p/Share	1,747 Reduced 3.98%	42,157 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	28,400 Added 38.74%	44,909 Common Stock
Dec 08 2022	SELL Open market or private sale	$86,222 $18.95 p/Share	4,550 Reduced 21.61%	16,509 Common Stock

KJW

Kory James Wentworth

Chief Financial Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Value

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Entrada Therapeutics, Inc.

Track Activities on TRDA

Account